Tesamorelin

This synthetic peptide is utilized to decrease excess abdominal fat in HIV-infected patients with lipodystrophy by promoting growth hormone production. It is marketed under the brand name Egrifta and is distinguished by its specific application in managing lipodystrophy associated with HIV. The primary beneficiaries of this treatment are HIV-infected individuals experiencing lipodystrophy-related abdominal fat accumulation.